Korean J Ophthalmol.  2005 Dec;19(4):264-268. 10.3341/kjo.2005.19.4.264.

Result of Photodynamic Therapy for Idiopathic Subfoveal Choroidal Neovascularization

• Yoo MH
• Boo HD
• Kim HK

• KMID: 754437
• DOI: http://doi.org/10.3341/kjo.2005.19.4.264

Abstract

PURPOSE
To investigate the factors that affect final vision following photodynamic therapy (PDT) for idiopathic subfoveal choroidal neovascularization (CNV). METHODS: A retrospective review of 16 patients whose eyes were diagnosed as idiopathic subfoveal CNV and were followed up for a minimum of 9 months. Statistical analysis was performed to investigate relationships between sex, age, size of the lesion, and initial vision compared to final vision. RESULTS: In the PDT group (10 eyes), the mean age of the patients was 34 years, mean size of the lesion was 1300 micrometer, mean initial vision was 20/60, and 7 of the 10 patients (70%) showed more than a two-line improvement in vision. Factors affecting final vision were sex (p=0.049), initial vision (p=0.0455), and size of the lesion (p=0.006). In the observation group (6 eyes), the mean age of the patients was 39 years, mean size of the lesion was 575 micrometer, mean initial vision was 20/32, and 5 of the 6 patients (83%) showed more than a two-line improvement in vision. CONCLUSIONS: The prognosis of idiopathic CNV was favorable as was reported in other studies. In the PDT group, statistically significant factors affecting final vision were initial vision, size of the lesion, and sex. However, since the number of patients sampled was insufficient and the average size of the lesions in the female patients was smaller, the size of the lesion seems to be the most important factor.

Keyword

Idiopathic subfoveal choroidal neovascularization (CNV) ; Photodynamic therapy (PDT)

MeSH Terms

Visual Acuity
Treatment Outcome
Retrospective Studies
*Photochemotherapy
Middle Aged
Male
Humans
Fundus Oculi
Fovea Centralis
Follow-Up Studies
Fluorescein Angiography
Female
Choroidal Neovascularization/*drug therapy/pathology/physiopathology
Adult

Reference

1. Cleasby GW. Idiopathic focal subretinal neovascularization. Am J Ophthalmol. 1976. 81:590–596.

2. Cohen SY, Laroche A, Leguen Y, et al. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996. 103:1241–1244.

3. Macular Photocoagulation Study Group. Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol. 1983. 101:1358–1361.

4. Macular Photocoagulation Study Group. Krypton laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol. 1990. 108:832–837.

5. Thomas MA, Grand MG, Williams DF, et al. Surgical management of subfoveal choroidal neovascularization. Ophthalmology. 1992. 99:952–968.

6. Fujii GY, Pieramici DJ, Humayun MS, et al. Complication associated with limited macular translocation. Am J Ophthalmol. 2000. 130:751–762.

7. Reichel E, Berrocal AM, Ip M, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology. 1999. 106:1908–1914.

8. Spraide RF, Guyer DR, McCormick B, et al. External beam radiation therapy for choroidal neovascularization. Ophthalmology. 1998. 105:24–30.

9. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trial - TAP report. Arch Ophthalmol. 1999. 117:1329–1345.

10. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporpin in photodynamic therapy report 2. Am J Ophthalmol. 2001. 131:541–560.

11. Ho AC, Yannuzzi LA, Pisicano K, et al. The natural history of idiopathic choroidal subfoveal neovascularization. Ophthalmology. 1995. 102:782–789.

12. Verteporfin round table 200 and 2001 participants. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators. Verteporfin in photodynamic therapy (VIP) study principal investigators. Guideline for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 2002. 22:6–18.

13. Iida T, Hagimura N, Kishi S, et al. Indocyanine green angiographic features of idiopathic submacular choroidal neovascularization. Am J Ophthalmol. 1998. 126:70–76.

14. Saari M. Disciform detachment of the macular, fluorescein and ICG fluorescence of angiographic findings in juvenile hemorrhage macular choroidopathy. Acta Ophthalmol. 1077. 55:530–538.

15. Ahn JK, Chung H, Yu HG. Natural history and visual prognosis of idiopathic choroidal neovascularization. J Korean Ophthalmol Soc. 2003. 44:665–662.

16. Thomas MA, Dickinson JD, Melberg NS, et al. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology. 1994. 101:1384–1396.

17. Melberg NS, Thomas MA, Burgess DB. The subfoveal removal of subfoveal choroidal neovascularization. Retina. 1996. 16:190–195.

18. Shiraga F, Shiragami C, Matsuo T, et al. Identification of ingrowth site of idiopathic subfoveal choroidal neovascularization by indocyanine green angiography. Ophthalmology. 2000. 107:600–607.

19. Gass JDM. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal choroidal neovascular membranes. Am J Ophthalmol. 1994. 118:285–298.

20. Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgicallyexcised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol. 1998. 126:59–69.

21. Grossniklaus HE, Hutchinson AK, Capone A, et al. Clinicopathologic features of surgically excised choroidal neovascular membranes. Ophthalmology. 1994. 101:1099–1111.

22. Campochiaro PA, Morgan KM, Conway BP, Stathos J. Spontaneous involution of subfoveal neovascularization. Am J Ophthalmol. 1990. 109:668–675.

23. Itagaki T, Ohkuma H, Kato N. Studies on experimental subretinal neovascularization: Regression of new vessels. Nippon Ganka Gakkai Zashi. 1985. 89:941–948.

24. Miller H, Miller B, Ryan SJ. The role of retinal pigment epithelium in the involution of subretinal neovascularization. Invest Ophthalmol Vis Sci. 1986. 27:1644–1652.

25. Glaser BM, Campochiaro PA, Davis JL Jr, et al. Retinal pigment epithelial cells release inhibitors of neovascularization. Ophthalmology. 1987. 94:780–784.

26. Spaide RF, Martin ML, Slakter J, et al. Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol. 2002. 134:62–68.